IB 

Union Calendar No. 196 

112TH CONGRESS 

1ST SESSION H. R. 1254 

[Report No. 112–295, Parts I and II] 

To amend the Controlled Substances Act to place synthetic drugs in Schedule 

I. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 30, 2011 

Mr. DENT (for himself, Mr. MEEHAN, Mr. MARINO, Mr. PLATTS, Mr. 

BARLETTA, Mr. CUELLAR, Mrs. EMERSON, Mrs. BIGGERT, Mr. LATOURETTE, Mr. GIBSON, Mr. STIVERS, and Mr. REED) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period 

to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee 

concerned 

NOVEMBER 22, 2011 

Reported from the Committee on Energy and Commerce with an amendment 

[Strike out all after the enacting clause and insert the part printed in italic] 

NOVEMBER 22, 2011 

Additional sponsors: Mr. HOLDEN, Mr. BOSWELL, Mr. LATHAM, Mr. 

LOEBSACK, Mr. DEFAZIO, Mr. DOLD, Mr. LANCE, Mr. MURPHY of Pennsylvania, Mrs. BONO MACK, Mr. MICHAUD, Ms. PINGREE of Maine, and 

Mr. GOWDY

NOVEMBER 22, 2011 

Reported from the Committee on the Judiciary with an amendment, committed to the Committee of the Whole House on the State of the Union, 

and ordered to be printed 

[Strike out all after the enacting clause and insert the part printed in boldface roman] 

[For text of introduced bill, see copy of bill as introduced on March 30, 2011] 

mstockstill on DSK4VPTVN1PROD with BILLS

2 

•HR 1254 RH

A BILL 

To amend the Controlled Substances Act to place synthetic 

drugs in Schedule I. 

mstockstill on DSK4VPTVN1PROD with BILLS

3 

•HR 1254 RH

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Synthetic Drug Control 

5 Act of 2011’’. 

6 SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I 

7 OF THE CONTROLLED SUBSTANCES ACT. 

8 (a) CANNABIMIMETIC AGENTS.—Schedule I, as set 

9 forth in section 202(c) of the Controlled Substances Act (21 

10 U.S.C. 812(c)) is amended by adding at the end the fol11 lowing: 

12 ‘‘(d)(1) Unless specifically exempted or unless listed in 

13 another schedule, any material, compound, mixture, or 

14 preparation which contains any quantity of 

15 cannabimimetic agents, or which contains their salts, iso16 mers, and salts of isomers whenever the existence of such 

17 salts, isomers, and salts of isomers is possible within the 

18 specific chemical designation. 

19 ‘‘(2) In paragraph (1): 

20 ‘‘(A) The term ‘cannabimimetic agents’ means 

21 any substance that is a cannabinoid receptor type 1 

22 (CB1 receptor) agonist as demonstrated by binding 

23 studies and functional assays within any of the fol24 lowing structural classes: 

mstockstill on DSK4VPTVN1PROD with BILLS

4 

•HR 1254 RH

1 ‘‘(i) 2-(3-hydroxycyclohexyl)phenol with 

2 substitution at the 5-position of the phenolic ring 

3 by alkyl or alkenyl, whether or not substituted on 

4 the cyclohexyl ring to any extent. 

5 ‘‘(ii) 3-(1-naphthoyl)indole or 3-(1- 

6 naphthylmethane)indole by substitution at the 

7 nitrogen atom of the indole ring, whether or not 

8 further substituted on the indole ring to any ex9 tent, whether or not substituted on the naphthoyl 

10 or naphthyl ring to any extent. 

11 ‘‘(iii) 3-(1-naphthoyl)pyrrole by substi12 tution at the nitrogen atom of the pyrrole ring, 

13 whether or not further substituted in the pyrrole 

14 ring to any extent, whether or not substituted on 

15 the naphthoyl ring to any extent. 

16 ‘‘(iv) 1-(1-naphthylmethylene)indene by sub17 stitution of the 3-position of the indene ring, 

18 whether or not further substituted in the indene 

19 ring to any extent, whether or not substituted on 

20 the naphthyl ring to any extent. 

21 ‘‘(v) 3-phenylacetylindole or 3-benzoylindole 

22 by substitution at the nitrogen atom of the indole 

23 ring, whether or not further substituted in the 

24 indole ring to any extent, whether or not sub25 stituted on the phenyl ring to any extent. 

mstockstill on DSK4VPTVN1PROD with BILLS

5 

•HR 1254 RH

1 ‘‘(B) Such term includes— 

2 ‘‘(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3- 

3 hydroxycyclohexyl]-phenol (CP-47,497); 

4 ‘‘(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3- 

5 hydroxycyclohexyl]-phenol (cannabicyclohexanol 

6 or CP-47,497 C8-homolog); 

7 ‘‘(iii) 1-pentyl-3-(1-naphthoyl)indole (JWH8 018 and AM678); 

9 ‘‘(iv) 1-butyl-3-(1-naphthoyl)indole (JWH10 073); 

11 ‘‘(v) 1-hexyl-3-(1-naphthoyl)indole (JWH12 019); 

13 ‘‘(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naph14 thoyl)indole (JWH-200); 

15 ‘‘(vii) 1-pentyl-3-(2- 

16 methoxyphenylacetyl)indole (JWH-250); 

17 ‘‘(viii) 1-pentyl-3-[1-(4- 

18 methoxynaphthoyl)]indole (JWH-081); 

19 ‘‘(ix) 1-pentyl-3-(4-methyl-1-naph20 thoyl)indole (JWH-122); 

21 ‘‘(x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole 

22 (JWH-398); 

23 ‘‘(xi) 1-(5-fluoropentyl)-3-(1-naph24 thoyl)indole (AM2201); 

mstockstill on DSK4VPTVN1PROD with BILLS

6 

•HR 1254 RH

1 ‘‘(xii) 1-(5-fluoropentyl)-3-(2- 

2 iodobenzoyl)indole (AM694); 

3 ‘‘(xiii) 1-pentyl-3-[(4-methoxy)-ben4 zoyl]indole (SR-19 and RCS-4); 

5 ‘‘(xiv) 1-cyclohexylethyl-3-(2- 

6 methoxyphenylacetyl)indole (SR-18 and RCS-8); 

7 and 

8 ‘‘(xv) 1-pentyl-3-(2- 

9 chlorophenylacetyl)indole (JWH-203).’’. 

10 (b) OTHER DRUGS.—Schedule I of section 202(c) of 

11 the Controlled Substances Act (21 U.S.C. 812(c)) is amend12 ed in subsection (c) by adding at the end the following: 

13 ‘‘(18) 4-methylmethcathinone (Mephedrone). 

14 ‘‘(19) 3,4-methylenedioxypyrovalerone (MDPV). 

15 ‘‘(20) 3,4-methylenedioxymethcathinone 

16 (methylone). 

17 ‘‘(21) Naphthylpyrovalerone (naphyrone). 

18 ‘‘(22) 4-fluoromethcathinone (flephedrone). 

19 ‘‘(23) 4-methoxymethcathinone (methedrone; Bk20 PMMA). 

21 ‘‘(24) Ethcathinone (N-Ethylcathinone). 

22 ‘‘(25) 3,4-methylenedioxyethcathinone (ethylone). 

23 ‘‘(26) Beta-keto-N-methyl-3,4- 

24 benzodioxyolybutanamine (butylone). 

25 ‘‘(27) N,N-dimethylcathinone (metamfepramone). 

mstockstill on DSK4VPTVN1PROD with BILLS

7 

•HR 1254 RH

1 ‘‘(28) Alpha-pyrrolidinopropiophenone (alpha2 PPP). 

3 ‘‘(29) 4-methoxy-alpha-pyrrolidinopropiophenone 

4 (MOPPP). 

5 ‘‘(30) 3,4-methylenedioxy-alpha6 pyrrolidinopropiophenone (MDPPP). 

7 ‘‘(31) Alpha-pyrrolidinovalerophenone (alpha8 PVP). 

9 ‘‘(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol10 6-amine) (MDAI). 

11 ‘‘(33) 3-fluoromethcathinone. 

12 ‘‘(34) 4’-Methyl-α-pyrrolidinobutiophenone 

13 (MPBP).’’. 

14 SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT 

15 HAZARDS TO PUBLIC SAFETY EXPANSION. 

16 Section 201(h)(2) of the Controlled Substances Act (21 

17 U.S.C. 811(h)(2)) is amended— 

18 (1) by striking ‘‘one year’’ and inserting ‘‘2 

19 years’’; and 

20 (2) by striking ‘‘six months’’ and inserting ‘‘1 

21 year’’. 

22 SECTION 1. SHORT TITLE. 

23 This Act may be cited as the ‘‘Synthetic 

24 Drug Control Act of 2011’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

8 

•HR 1254 RH

1 SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I 

2 OF THE CONTROLLED SUBSTANCES ACT. 

3 (a) CANNABIMIMETIC AGENTS.—Schedule I, 

4 as set forth in section 202(c) of the Controlled 

5 Substances Act (21 U.S.C. 812(c)) is amended 

6 by adding at the end the following: 

7 ‘‘(d)(1) Unless specifically exempted or un8 less listed in another schedule, any material, 

9 compound, mixture, or preparation which 

10 contains any quantity of cannabimimetic 

11 agents, or which contains their salts, isomers, 

12 and salts of isomers whenever the existence 

13 of such salts, isomers, and salts of isomers is 

14 possible within the specific chemical designa15 tion. 

16 ‘‘(2) In paragraph (1): 

17 ‘‘(A) The term ‘cannabimimetic 

18 agents’ means any substance that is a 

19 cannabinoid receptor type 1 (CB1 recep20 tor) agonist as demonstrated by binding 

21 studies and functional assays within any 

22 of the following structural classes: 

23 ‘‘(i) 2-(3-hydroxycyclohexyl)phenol 

24 with substitution at the 5-position of 

25 the phenolic ring by alkyl or alkenyl, 

mstockstill on DSK4VPTVN1PROD with BILLS

9 

•HR 1254 RH

1 whether or not substituted on the 

2 cyclohexyl ring to any extent. 

3 ‘‘(ii) 3-(1-naphthoyl)indole or 3-(1- 

4 naphthylmethane)indole by substi5 tution at the nitrogen atom of the 

6 indole ring, whether or not further 

7 substituted on the indole ring to any 

8 extent, whether or not substituted on 

9 the naphthoyl or naphthyl ring to any 

10 extent. 

11 ‘‘(iii) 3-(1-naphthoyl)pyrrole by 

12 substitution at the nitrogen atom of 

13 the pyrrole ring, whether or not fur14 ther substituted in the pyrrole ring to 

15 any extent, whether or not sub16 stituted on the naphthoyl ring to any 

17 extent. 

18 ‘‘(iv) 1-(1- 

19 naphthylmethylene)indene by substi20 tution of the 3-position of the indene 

21 ring, whether or not further sub22 stituted in the indene ring to any ex23 tent, whether or not substituted on 

24 the naphthyl ring to any extent. 

mstockstill on DSK4VPTVN1PROD with BILLS

10 

•HR 1254 RH

1 ‘‘(v) 3-phenylacetylindole or 3- 

2 benzoylindole by substitution at the 

3 nitrogen atom of the indole ring, 

4 whether or not further substituted in 

5 the indole ring to any extent, whether 

6 or not substituted on the phenyl ring 

7 to any extent. 

8 ‘‘(B) Such term includes— 

9 ‘‘(i) 5-(1,1-dimethylheptyl)-2- 

10 [(1R,3S)-3-hydroxycyclohexyl]-phenol 

11 (CP–47,497); 

12 ‘‘(ii) 5-(1,1-dimethyloctyl)-2- 

13 [(1R,3S)-3-hydroxycyclohexyl]-phenol 

14 (cannabicyclohexanol or CP–47,497 

15 C8-homolog); 

16 ‘‘(iii) 1-pentyl-3-(1-naph17 thoyl)indole (JWH–018 and AM678); 

18 ‘‘(iv) 1-butyl-3-(1-naphthoyl)indole 

19 (JWH–073); 

20 ‘‘(v) 1-hexyl-3-(1-naphthoyl)indole 

21 (JWH–019); 

22 ‘‘(vi) 1-[2-(4-morpholinyl)ethyl]-3- 

23 (1-naphthoyl)indole (JWH–200); 

mstockstill on DSK4VPTVN1PROD with BILLS

11 

•HR 1254 RH

1 ‘‘(vii) 1-pentyl-3-(2- 

2 methoxyphenylacetyl)indole (JWH– 

3 250); 

4 ‘‘(viii) 1-pentyl-3-[1-(4- 

5 methoxynaphthoyl)]indole (JWH–081); 

6 ‘‘(ix) 1-pentyl-3-(4-methyl-1-naph7 thoyl)indole (JWH–122); 

8 ‘‘(x) 1-pentyl-3-(4-chloro-1-naph9 thoyl)indole (JWH–398); 

10 ‘‘(xi) 1-(5-fluoropentyl)-3-(1-naph11 thoyl)indole (AM2201); 

12 ‘‘(xii) 1-(5-fluoropentyl)-3-(2- 

13 iodobenzoyl)indole (AM694); 

14 ‘‘(xiii) 1-pentyl-3-[(4-methoxy)-ben15 zoyl]indole (SR–19 and RCS–4); 

16 ‘‘(xiv) 1-cyclohexylethyl-3-(2- 

17 methoxyphenylacetyl)indole (SR–18 

18 and RCS–8); and 

19 ‘‘(xv) 1-pentyl-3-(2- 

20 chlorophenylacetyl)indole (JWH– 

21 203).’’. 

22 (b) OTHER DRUGS.—Schedule I of section 

23 202(c) of the Controlled Substances Act (21 

24 U.S.C. 812(c)) is amended in subsection (c) by 

25 adding at the end the following: 

mstockstill on DSK4VPTVN1PROD with BILLS

12 

•HR 1254 RH

1 ‘‘(18) 4-methylmethcathinone 

2 (Mephedrone). 

3 ‘‘(19) 3,4-methylenedioxypyrovalerone 

4 (MDPV). 

5 ‘‘(20) 3,4- 

6 methylenedioxymethcathinone 

7 (methylone). 

8 ‘‘(21) Naphthylpyrovalerone 

9 (naphyrone). 

10 ‘‘(22) 4-fluoromethcathinone 

11 (flephedrone). 

12 ‘‘(23) 4-methoxymethcathinone 

13 (methedrone; Bk–PMMA). 

14 ‘‘(24) Ethcathinone (N15 Ethylcathinone). 

16 ‘‘(25) 3,4-methylenedioxyethcathinone 

17 (ethylone). 

18 ‘‘(26) Beta-keto-N-methyl-3,4- 

19 benzodioxyolybutanamine (butylone). 

20 ‘‘(27) N,N-dimethylcathinone 

21 (metamfepramone). 

22 ‘‘(28) Alpha23 pyrrolidinopropiophenone (alpha-PPP). 

24 ‘‘(29) 4-methoxy-alpha25 pyrrolidinopropiophenone (MOPPP). 

mstockstill on DSK4VPTVN1PROD with BILLS

13 

•HR 1254 RH

1 ‘‘(30) 3,4-methylenedioxy2 alphapyrrolidinopropiophenone 

3 (MDPPP). 

4 ‘‘(31) Alpha-pyrrolidinovalerophenone 

5 (alpha-PVP). 

6 ‘‘(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3- 

7 dioxol-6-amine) (MDAI). 

8 ‘‘(33) 3-fluoromethcathinone. 

9 ‘‘(34) 4’-Methyl-α10 pyrrolidinobutiophenone (MPBP). 

11 ‘‘(35) 2-(2,5-Dimethoxy-4- 

12 ethylphenyl)ethanamine (2C–E). 

13 ‘‘(36) 2-(2,5-Dimethoxy-4- 

14 methylphenyl)ethanamine (2C–D). 

15 ‘‘(37) 2-(4-Chloro-2,5- 

16 dimethoxyphenyl)ethanamine (2C–C). 

17 ‘‘(38) 2-(4-Iodo-2,5- 

18 dimethoxyphenyl)ethanamine (2C–I). 

19 ‘‘(39) 2-[4-(Ethylthio)-2,5- 

20 dimethoxyphenyl]ethanamine (2C–T–2). 

21 ‘‘(40) 2-[4-(Isopropylthio)-2,5- 

22 dimethoxyphenyl]ethanamine (2C–T–4). 

23 ‘‘(41) 2-(2,5- 

24 Dimethoxyphenyl)ethanamine (2C–H). 

mstockstill on DSK4VPTVN1PROD with BILLS

14 

•HR 1254 RH

1 ‘‘(42) 2-(2,5-Dimethoxy-4-nitro2 phenyl)ethanamine (2C–N). 

3 ‘‘(43) 2-(2,5-Dimethoxy-4-(n)- 

4 propylphenyl)ethanamine (2C–P).’’. 

5 SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT 

6 HAZARDS TO PUBLIC SAFETY EXPANSION. 

7 Section 201(h)(2) of the Controlled Sub8 stances Act (21 U.S.C. 811(h)(2)) is amended— 

9 (1) by striking ‘‘one year’’ and insert10 ing ‘‘2 years’’; and 

11 (2) by striking ‘‘six months’’ and in12 serting ‘‘1 year’’. 

mstockstill on DSK4VPTVN1PROD with BILLS

mstockstill on DSK4VPTVN1PROD with BILLS

Union Calendar No. 196 

112TH CONGRESS 

1ST SESSION H. R. 1254 

[Report No. 112–295, Parts I and II] 

A BILL 

To amend the Controlled Substances Act to place 

synthetic drugs in Schedule I. 

NOVEMBER 22, 2011 

Reported from the Committee on Energy and Commerce 

N

with an amendment 

OVEMBER 22, 2011 

Reported from the Committee on the Judiciary with an 

printed House on the State of the Union, and ordered to be amendment, committed to the Committee of the Whole 

mstockstill on DSK4VPTVN1PROD with BILLS